WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Breast Cancer Endpoints - Master Primary m6a, Neoadjuvant setting has_component Overall Survival (OS), FDA Criteria for Efficacy endpoints for Breast Cancer treatment has_pertinent_information Tumor Biopsy, Main concept groups (e.g. Primary endpoints) are denoted by Larger bold font with thicker outline, Non-measurable lesions has_subtype Cystic lesion, Positive has_follow_up Axillary dissection, Lymph node examination measured_over Quantity of nodes, Adjuvant setting has_component Disease free survival (DFS), Lymph node examination has_additional _info Lymph node details, FDA Criteria for Efficacy endpoints for Breast Cancer treatment has_pertinent_information Cancer stage, Tumor assessment is_derived_from RECIST v1.1 criteria, Target lesion has_component Quantitative assessment, Neoadjuvant setting has_component Pathologic complete response (pCR), Demographics/Medical history has_components >Age >Ethnicity >Pregnancy status >BRCA1/2 mutation >Gene expression >Co-morbidities, Concepts (e.g. CRF:pCR:Surgical margins are denoted by solid round-edged rectangle, Baseline assessment has_pertinent_information Image acquisition, Disease free survival (DFS) provides_ evidence_for Disease recurrence, Surgery includes_evaluation_of Breast specimen, Disease progression validated_by Tumor assessment, Repeated concepts/instances are denoted by dotted outline, Advanced setting has_component Progression free survival (PFS)